42 CFR § 2.36 - Disclosures to prescription drug monitoring programs.

---
identifier: "/us/cfr/t42/s2.36"
source: "ecfr"
legal_status: "authoritative_unofficial"
title: "42 CFR § 2.36 - Disclosures to prescription drug monitoring programs."
title_number: 42
title_name: "Public Health"
section_number: "2.36"
section_name: "Disclosures to prescription drug monitoring programs."
chapter_name: "PUBLIC HEALTH SERVICE, DEPARTMENT OF HEALTH AND HUMAN SERVICES"
subchapter_number: "A"
subchapter_name: "GENERAL PROVISIONS"
part_number: "2"
part_name: "CONFIDENTIALITY OF SUBSTANCE USE DISORDER PATIENT RECORDS"
positive_law: false
currency: "2026-03-24"
last_updated: "2026-03-24"
format_version: "1.1.0"
generator: "[email protected]"
authority: "42 U.S.C. 290dd-2; 42 U.S.C. 290dd-2 note."
regulatory_source: "82 FR 6115, Jan. 18, 2017, unless otherwise noted."
cfr_part: "2"
---


# 2.36 Disclosures to prescription drug monitoring programs.

A part 2 program or other lawful holder is permitted to report any SUD medication prescribed or dispensed by the part 2 program to the applicable state prescription drug monitoring program if required by applicable state law. A part 2 program or other lawful holder must obtain patient consent to a disclosure of records to a prescription drug monitoring program under § 2.31 prior to reporting of such information.

[85 FR 43038, July 15, 2020]